Figure 3: Guanabenz protects oligodendrocytes and myelin from IFN-γ-mediated loss in vivo. | Nature Communications

Figure 3: Guanabenz protects oligodendrocytes and myelin from IFN-γ-mediated loss in vivo.

From: Pharmaceutical integrated stress response enhancement protects oligodendrocytes and provides a potential multiple sclerosis therapeutic

Figure 3

(a–c) Immunofluorescent staining for MBP and ASPA, a mature oligodendrocyte marker, in the medial corpus callosum of (a) vehicle-treated wild-type littermates, (b) vehicle-treated GFAP/tTA;TRE-IFN-γ transgenic mice and (c) guanabenz-treated GFAP/tTA;TRE-IFN-γ mice at P18. Mice were treated with vehicle or 4 mg kg−1 of guanabenz daily from P7 to P18. (d) Quantification of ASPA+ cells in the medial corpus callosum of wild type littermates and GFAP/tTA;TRE-IFN-γ mice treated with vehicle or guanabenz. Images represent four to six mice per group; graph represents the average of values from four to six mice per group. Unpaired t-test, **P<0.005, #P<0.05 as compared with vehicle-treated control. Scale bar, 200 μm. Data are presented as mean±s.e.m.

Back to article page